These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18822711)

  • 21. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB
    Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.
    Dior M; Coriat R; Mir O; Brezault C; Perkins G; Dhooge M; Goldwasser F; Chaussade S
    Am J Med; 2012 Aug; 125(8):828-30. PubMed ID: 22840668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
    Okines A; Cunningham D
    Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
    Ryan EM; Hanly A; Morrin MM; McNamara DA
    J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Klinger M; Tamandl D; Eipeldauer S; Hacker S; Herberger B; Kaczirek K; Dorfmeister M; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2010 Aug; 17(8):2059-65. PubMed ID: 20177795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Vaidyanathan G; Groman A; Wilding G; Fakih MG
    Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 32. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
    Gibson TB; Grothey E; Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
    Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
    Reddy GK
    Clin Colorectal Cancer; 2005 Jan; 4(5):300-1. PubMed ID: 15663832
    [No Abstract]   [Full Text] [Related]  

  • 35. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
    Rossi L; Veltri E; Zullo A; Zoratto F; Colonna M; Di Seri M; Longo F; Mottolese M; Giannarelli D; Ruco L; Romiti A; Barucca V; Adua D; Tomao S
    Future Oncol; 2012 Sep; 8(9):1193-7. PubMed ID: 23030493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab in the treatment of colorectal cancer.
    Marshall JL
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
    [No Abstract]   [Full Text] [Related]  

  • 38. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
    Bertolini F; Malavasi N; Scarabelli L; Fiocchi F; Bagni B; Del Giovane C; Colucci G; Gerunda GE; Depenni R; Zironi S; Fontana A; Pettorelli E; Luppi G; Conte PF
    Br J Cancer; 2011 Mar; 104(7):1079-84. PubMed ID: 21386839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Rodriguez NA; Ascaso FJ
    J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
    [No Abstract]   [Full Text] [Related]  

  • 40. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.